Expected Costs, QALYs and ICER over 3 years for the cohort of 272 patients for each treatment approach
| Discounted | Usual care (UC) | Personalised care (PC) | Difference (PC-UC) 2.5% to 97.5% CI |
|---|---|---|---|
| Direct costs | € 4 261 555 | € 4 238 248 | −€ 23 307 |
| −€ 56 058 to € 49 346 | |||
| Productivity costs | € 1 875 160 | € 1 859 802 | −€ 15 357 |
| −€ 225 986 to € 195 370 | |||
| Drug costs | € 12 009 964 | € 9 678 572 | −€ 2 314 354 |
| Testing costs | € 0 | € 10 872.52 | € 10 872.52 |
| Total costs | € 18 028 517 | € 15 466 869 | −€ 2 561 648 |
| −€ 3 252 529 to € −1 898 087 | |||
| QALYs | 587.81 | 591.65 | 3.84 |
| −8.39 to 16.20 | |||
| Healthcare ICER | −€ 646 266/QALY | ||
| Societal ICER | −€ 666 541/QALY |
Represented values are discounted for costs and effects at 4% and 1.5% respectively. The results represent mean of 5000 simulations.
ICER, incremental cost-effectiveness ratio; PC, personalised care; QALY, quality adjusted life year; UC, usual care.